
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary end goal in the marginal zone lymphoma cohort, which evaluated the efficacy of Breyanzi (lisocabtagene maraleucel), according to a …